A Randomized, Double-Blind Study Evaluating the Safety and Effectiveness of a TYK2 Inhibitor for Moderate to Severe Plaque Psoriasis in Adults

What this Trial Is About

Researchers are evaluating the effectiveness and safety of a TYK2 inhibitor in adults with moderate to severe plaque psoriasis. This study aims to understand how well this drug works to improve symptoms over a 12-week treatment period. Participants will be adults between 18 and 70 years old who have had plaque psoriasis for at least six months. Participants will be randomly assigned to receive one of three different doses of the TYK2 inhibitor or a placebo. The treatment is given according to specific dosing schedules over 12 weeks. This double-blind study means neither participants nor researchers know who is receiving the active drug or placebo during the trial. During the study, participants will have regular assessments to monitor their skin condition using the PASI score and other measures like sPGA, DLQI, and body surface area affected by psoriasis. Blood samples will be taken at multiple time points to measure drug levels, and safety will be tracked by recording any adverse events. The study lasts about 12 weeks, with follow-ups to evaluate treatment effects and safety.

A Study to Evaluate Effectiveness and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis